多梳蛋白家族癌基因Bmi-1表达增加与肝细胞癌预后不良相关。
Increased polycomb-group oncogene Bmi-1 expression correlates with poor prognosis in hepatocellular carcinoma.
作者信息
Wang Hui, Pan Ke, Zhang Hua-kun, Weng De-sheng, Zhou Jun, Li Jian-jun, Huang Wei, Song Hai-feng, Chen Min-shan, Xia Jian-chuan
机构信息
State Key Laboratory of Oncology in Southern China and Department of Experimental Research, Sun Yat-sen University Cancer Center, 651 Dongfeng Road East, Yuexiu District, Guangzhou, Guangdong Province 510060, People's Republic of China.
出版信息
J Cancer Res Clin Oncol. 2008 May;134(5):535-41. doi: 10.1007/s00432-007-0316-8. Epub 2007 Oct 5.
PURPOSE
Recent studies have identified polycomb-group gene Bmi-1 as oncogene in the generation of mouse pre-cell lymphomas, and overexpression of Bmi-1 has been found in several human tumor with the disease progress and poor prognosis of the cancer patients.
METHODS
In present study, we investigated Bmi-1 expression and its prognostic significance in hepatocellular carcinoma (HCC) by performing immunohistochemical analysis, using a total of 137 HCC clinical tissue samples.
RESULTS
High Bmi-1 expression (Bmi-1 2+ or 3+) was shown in 29.9% cases. The positive immuno-staining of Bmi-1 was not only in well/moderately-differentiated tumor cells, but also in surrounding noncancerous or cirrhotic liver tissue. Bmi-1 expression level did not correlate with any clinicopathological parameters. However, survival analysis showed that the high-Bmi-1 group had a significantly shorter overall survival time than the low-Bmi-1 group (P=0.047). Multivariate analysis after 24 months revealed that Bmi-1 expression was a significant and independent prognostic parameter (P=0.002) for HCC patients.
CONCLUSIONS
Our study indicated that Bmi-1 could be a candidate biomarker for long-term survival in HCC.
目的
近期研究已确定多梳蛋白家族基因Bmi-1在小鼠前体淋巴瘤发生过程中为癌基因，并且在几种人类肿瘤中发现Bmi-1的过表达与疾病进展及癌症患者的不良预后相关。
方法
在本研究中，我们通过免疫组织化学分析，使用总共137份肝癌临床组织样本，研究了Bmi-1在肝细胞癌（HCC）中的表达及其预后意义。
结果
29.9%的病例显示Bmi-1高表达（Bmi-1 2+或3+）。Bmi-1的阳性免疫染色不仅出现在高/中分化肿瘤细胞中还出现在周围的非癌性或肝硬化肝组织中。Bmi-1表达水平与任何临床病理参数均无相关性。然而，生存分析显示，高Bmi-1组的总生存时间明显短于低Bmi-1组（P=0.047）。24个月后的多因素分析显示，Bmi-1表达是HCC患者的一个显著且独立的预后参数（P=0.002）。
结论
我们的研究表明，Bmi-1可能是HCC患者长期生存的一个候选生物标志物。
Zotero 插件